December 13, 20090ThromboGenics Starts Phase II Trial for Macular Degeneration Therapy ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD).
